Conversion from immediate- to extended-release cysteamine may decrease disease control and increase additional side effects
- PMID: 28255804
- DOI: 10.1007/s00467-017-3618-3
Conversion from immediate- to extended-release cysteamine may decrease disease control and increase additional side effects
Comment on
-
Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.Pediatr Nephrol. 2017 Jan;32(1):91-97. doi: 10.1007/s00467-016-3438-x. Epub 2016 Jun 27. Pediatr Nephrol. 2017. PMID: 27350621
References
-
- Pediatr Nephrol. 2017 Jan;32(1):91-97 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources